FDA digital chief signals upcoming AI regulatory guidance
STAT+ health-tech newsletter reported that the FDA’s digital leader offered a preview of forthcoming guidance on artificial intelligence. The briefing, delivered by Rick Abramson, highlighted the agency’s intent to refine its AI policy while providing few concrete details.
Abramson indicated that the FDA is actively reviewing how AI systems are evaluated and regulated, aiming to balance innovation with patient safety. He emphasized that future updates will clarify expectations for developers and users of AI-driven medical technologies.
Industry observers see the hints as a signal that more formal rules are on the horizon, which could affect product development timelines and compliance strategies. Companies are advised to stay alert to forthcoming announcements.
The piece appeared in a subscriber-only edition of STAT’s health-tech newsletter, underscoring the limited public information currently available.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: FDA digital leader hints at coming AI policy updates”
read at STAT ↗
comments(0)
5-min edit window · permanent after that